Polaryx Therapeutics, Inc. Common Stock

NASDAQ: PLYX · Healthcare · Biotechnology

PublicHQ Paramus, NJ · BergenCIK 0002075320Reports USD

#1 of 1,418 Healthcare companies by revenue

EA Score

——

FH 55DQ —GM —SS 32

v0.1 · 35/100 weight · pillars only

↑ Altman-Z, balance-sheet leverage · ↓ listing tenure, return on equity

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$9.0M

Employees

as of 2026-08-30

Market cap

$115.1M

as of 2026-08-30

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$9.0M-$9.0M2025

Operating income-$7.8M-$7.8M2025

Total assets$5.2M$5.2M2025

Liabilities$605.0k$605.0k2025

Equity$4.6M$4.6M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Polaryx Therapeutics, Inc. Common Stock’s financial profile?

Polaryx Therapeutics, Inc. Common Stock earned -$9.0M in FY2025 net income.

Peers · Healthcare

Indaptus Therapeutics, Inc.——NervGen Pharma Corp. Common stock——Milestone Pharmaceuticals Inc.——Nautilus Biotechnolgy, Inc.——enGene Holdings Inc.——Biomea Fusion, Inc.——

Neighbors

Bergen →

Becton, Dickinson and Company$21.8B83B+Balchem Corp$1.0B84B+Versant Media Group, Inc. Class A$6.7B56C Columbia Financial, Inc.——ADMA Biologics, Inc.$510.2M85A Innodata Inc.$251.7M81B+

Key facts

CEOAlex Yang

SectorHealthcare

IndustryBiotechnology

HeadquartersParamus, NJ

ExchangeNASDAQ: PLYX

Employees11

IPO date2026-02-02

Latest filings

10-Q2026-08-13 DEF 14A2026-07-28 8-K2026-07-21 8-K2026-07-17 8-K2026-05-28 10-Q2026-05-15 10-K2026-03-24

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.